From the Department of Psychology, University of South Carolina Aiken, Aiken, SC.
J ECT. 2020 Dec;36(4):279-284. doi: 10.1097/YCT.0000000000000680.
Current research on the efficacy of repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex as a noninvasive therapy for treatment-resistant depression is largely settled science. However, little is known about its efficacy with active-duty service members (ADSMs) with major depressive disorder. In a retrospective chart review, we examined depressive symptom ratings in ADSMs seeking treatment at the US Army Outpatient Behavioral Health Service Clinic at Eisenhower Army Medical Center, Fort Gordon, Ga.
We reviewed 121 consecutive outpatient charts, which yielded 61 ADSMs who completed a minimum of 20 rTMS sessions for refractory depression, and for whom both pretreatment and posttreatment depressive symptom ratings were available. Pre- and post-Patient Health Questionnaire 9 (PHQ-9) scores were subjected to a paired t test, and Reliable Change Indices were calculated to determine both reliable and clinical significance.
Average (SD) pretreatment and posttreatment PHQ-9 scores were 15.8 (6.2) and 12.6 (7.6), respectively. Statistically significant reduction in post-PHQ-9 was demonstrated (P < 0.001), with 69% of patients lowering their ratings and 31% demonstrating reliable change (improvement >5.64). Additionally, 20% demonstrated a reliable change that placed them in the nondysfunctional range (post-PHQ-9 <9.6), demonstrating clinical significance.
These data confirm a course of standard rTMS to ADSMs with major depression is promising in reducing depressive symptoms. Given that success and completion rates from this clinic are similar to those reported in civilian populations (80%), rTMS may be an adequate additional treatment or augmentation strategy for refractory depression in ADSMs.
目前关于经颅重复磁刺激(rTMS)左背外侧前额叶作为一种非侵入性治疗难治性抑郁症的疗效的研究已基本确定。然而,对于现役军人(ADSM)患有重度抑郁症的患者,其疗效知之甚少。在回顾性图表审查中,我们检查了在佐治亚州戈登堡的艾森豪威尔陆军医疗中心美国陆军门诊行为健康服务诊所寻求治疗的 ADSM 的抑郁症状评分。
我们回顾了 121 份连续门诊病历,其中有 61 名 ADSM 完成了至少 20 次 rTMS 治疗难治性抑郁症的疗程,并且有治疗前后的抑郁症状评分。对治疗前后患者健康问卷 9 (PHQ-9)评分进行配对 t 检验,并计算可靠变化指数以确定可靠和临床意义。
平均(SD)治疗前和治疗后 PHQ-9 评分分别为 15.8(6.2)和 12.6(7.6)。PHQ-9 后评分显示出统计学显著降低(P <0.001),69%的患者降低了他们的评分,31%表现出可靠的变化(改善> 5.64)。此外,20%的患者表现出可靠的变化,使他们处于非功能障碍范围(PHQ-9<9.6),表明具有临床意义。
这些数据证实了标准 rTMS 治疗 ADSM 重度抑郁症在减轻抑郁症状方面是有希望的。鉴于该诊所的成功率和完成率与平民群体(80%)相似,rTMS 可能是 ADSM 难治性抑郁症的一种有效的额外治疗或增强策略。